Nalls Sherbakoff Group’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Nalls Sherbakoff Group’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$42.7K	Hold	350	–	–	0.03%	217
2025 Q3	$35.1K	Hold	350	–	–	0.02%	237
2025 Q2	$29K	Buy	350 +100	+40%	+$7.98K	0.02%	250
2025 Q1	$20.3K	Buy	+250	New	+$22.3K	0.02%	247
2023 Q4	$28.3K	Buy	317 +67	+27%	+$4.98K	0.03%	210
2023 Q3	$18.3K	Hold	250	–	–	0.02%	228
2023 Q2	$21K	Hold	250	–	–	0.02%	223
2023 Q1	$18.7K	Buy	+250	New	+$20.7K	0.02%	235
2018 Q4	$18K	Buy	+250	New	+$20.1K	0.03%	223

Other funds holding XBI

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Nalls Sherbakoff Group's XBI Position: Q4 2025 in Review

Nalls Sherbakoff Group held its State Street SPDR S&P Biotech ETF (XBI) position steady in Q4 2025 at 350 shares worth $42.7K. The position accounts for 0.03% of the portfolio, ranked #217.

Nalls Sherbakoff Group first reported a position in XBI in Q4 2018 and has held it in 9 quarters since. 813 funds tracked by Wall St. Rank hold XBI as of Q4 2025.

Nalls Sherbakoff Group held 350 shares of State Street SPDR S&P Biotech ETF worth $42.7K as of Q4 2025.
Nalls Sherbakoff Group left its State Street SPDR S&P Biotech ETF share count unchanged in Q4 2025.
State Street SPDR S&P Biotech ETF made up 0.03% of Nalls Sherbakoff Group's portfolio in Q4 2025, its #217 holding.
Nalls Sherbakoff Group first reported a position in State Street SPDR S&P Biotech ETF in Q4 2018 and has held it in 9 quarters since.
813 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q4 2025.

Based on Nalls Sherbakoff Group's 13F filing for Q4 2025, filed 12 Mar 2026.